Loading...

Brian Druker (OHSU) Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib

8,341 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 29, 2010

https://www.ibiology.org/human-diseas...

Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. Although the majority of patients with chronic myeloid leukemia (CML) respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this information to treat successfully treat other malignant diseases driven by these kinases will be reviewed. See more at http://www.ibioseminars.org

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...